Cartesian Therapeutics (RNAC)
NASDAQ:RNAC
Top Page
Cartesian Therapeutics
(NASDAQ:RNAC)
Select Model
Select Model
Rating:44Neutral
Price Target:
$5.50
▼(-10.57% Downside)
Action:ReiteratedDate:03/28/26
The score is held down primarily by deteriorating financial performance (sharp revenue compression, widening losses, and heavy cash burn with negative equity) and a bearish technical trend (below major moving averages with negative MACD). A positive corporate update and stated cash runway into mid-2027 provide some offset, but valuation support is limited due to ongoing losses and no dividend yield data.
Positive Factors
Phase 3 initiation and durable Phase 2b data
Initiation of a Phase 3 AURORA trial following deep, durable Phase 2b responses materially de-risks the lead program. A successful Phase 3 would validate the therapy commercially for myasthenia gravis, unlock larger-market opportunity and attract partners or financing over a multi-quarter horizon.
Negative Factors
Sharp revenue collapse and widening net losses
A precipitous revenue decline alongside materially larger net losses signals weak commercial or milestone inflows and deteriorating profitability. This persistent earnings shortfall undermines self-funding ability, heightens execution risk, and makes long-term investment dependent on successful clinical milestones or external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 3 initiation and durable Phase 2b data
Initiation of a Phase 3 AURORA trial following deep, durable Phase 2b responses materially de-risks the lead program. A successful Phase 3 would validate the therapy commercially for myasthenia gravis, unlock larger-market opportunity and attract partners or financing over a multi-quarter horizon.
Read all positive factors
Cartesian Therapeutics (RNAC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$163.03M
Dividend YieldN/A
Average Volume (3M)242.83K
Price to Earnings (P/E)―
Beta (1Y)2.14
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees66
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.46
Shares Outstanding26,509,024
10 Day Avg. Volume130,101
30 Day Avg. Volume242,827
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-1.48
Price to Sales (P/S)66.95
P/FCF Ratio-2.36
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue18.36
Enterprise Value/Gross Profit-5.14
Enterprise Value/Ebitda-0.84
Forecast
1Y Price Target
$34.00Price Target Upside452.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-3.42
Revenue Forecast (FY)$672.57K
Cartesian Therapeutics Business Overview & Revenue Model
Company Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy p...
How the Company Makes Money
null...
Cartesian Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
28
Negative
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.80M | 38.91M | 26.00M | 110.78M | 85.08M |
| Gross Profit | 2.80M | 38.91M | 26.00M | 108.74M | 85.08M |
| EBITDA | -86.70M | -75.99M | -235.03M | 39.84M | -5.16M |
| Net Income | -130.30M | -77.42M | -219.71M | 35.38M | -25.69M |
Balance Sheet | |||||
| Total Assets | 296.41M | 435.02M | 305.05M | 165.89M | 159.88M |
| Cash, Cash Equivalents and Short-Term Investments | 125.14M | 212.61M | 76.91M | 134.60M | 128.06M |
| Total Debt | 12.68M | 13.98M | 10.96M | 37.92M | 35.28M |
| Total Liabilities | 422.65M | 441.82M | 745.23M | 72.06M | 137.36M |
| Stockholders Equity | -126.24M | -6.80M | -440.18M | 93.83M | 22.52M |
Cash Flow | |||||
| Free Cash Flow | -79.39M | -32.77M | -51.37M | -32.83M | -61.47M |
| Operating Cash Flow | -73.94M | -23.67M | -51.16M | -31.63M | -60.38M |
| Investing Cash Flow | -5.45M | -8.74M | 34.61M | -15.00M | -17.14M |
| Financing Cash Flow | -8.05M | 168.43M | -13.14M | 39.22M | 52.90M |
Cartesian Therapeutics Technical Analysis
Negative
6.15
Price Trends
6.92
Negative
7.15
Negative
8.83
Negative
Market Momentum
-0.30
Positive
41.85
Neutral
62.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNAC, the sentiment is Negative. The current price of 6.15 is below the 20-day moving average (MA) of 6.61, below the 50-day MA of 6.92, and below the 200-day MA of 8.83, indicating a bearish trend. The MACD of -0.30 indicates Positive momentum. The RSI at 41.85 is Neutral, neither overbought nor oversold. The STOCH value of 62.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNAC.
Cartesian Therapeutics Risk Analysis
Cartesian Therapeutics disclosed 45 risk factors in its most recent earnings report. Cartesian Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cartesian Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $382.08M | 9.56 | 27.78% | ― | -12.96% | 56.02% | |
57 Neutral | $472.46M | -1.84 | -46.34% | ― | ― | 14.33% | |
52 Neutral | $1.18B | -3.63 | -189.50% | ― | ― | 1.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $233.63M | -1.93 | -51.35% | ― | -80.88% | -388.61% | |
47 Neutral | $769.10M | 0.02 | 72.70% | ― | ― | -1072.48% | |
44 Neutral | $163.03M | -1.44 | 279.62% | ― | ― | ― |
* Healthcare Sector Average
RNAC
Cartesian Therapeutics
6.15
-4.21
-40.64%
PBYI
Puma Biotechnology
7.51
4.77
174.09%
DBVT
DBV Technologies SA - American
21.51
14.32
199.17%
VYGR
Voyager Therapeutics
3.92
0.93
31.10%
AVIR
Atea Pharmaceuticals
5.93
3.24
120.45%
VOR
Vor Biopharma
15.75
3.27
26.26%
Cartesian Therapeutics Corporate Events
Business Operations and StrategyFinancial Disclosures
Cartesian Therapeutics Outlines 2026 Outlook and Trial Progress
Positive
Jan 9, 2026
On January 9, 2026, Cartesian Therapeutics reported recent progress and its 2026 outlook, highlighting strong Phase 2b data for Descartes-08 in myasthenia gravis, where deep and durable responses were observed through 12 months after a single outp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.